基本信息
文件名称:Brigatinib-d11-AP-26113-d-sub-11-sub-生命科学试剂-MCE.pdf
文件大小:462.63 KB
总页数:1 页
更新时间:2025-05-23
总字数:约3.17千字
文档摘要

Hotline:400-820-3792

Inhibitors?ScreeningLibraries?Proteins

www.MedChemE

Brigatinib-d11

Cat.No.:HY-12857S2

CASNo.:2055306-76-6

Synonyms:AP-26113-d11

分?式:C??H??D??ClN?O?P

分?量:595.16

作?靶点:Isotope-LabeledCompounds;Anaplasticlymphomakinase

(ALK)

作?通路:Others;ProteinTyrosineKinase/RTK

储存?式:Pleasestoretheproductundertherecommendedconditionsin

theCertificateofAnalysis.

BIOLOGICALACTIVITY

?物活性Brigatinib-d11(AP-26113-d11)是氘代标记的Brigatinib.Brigatinib(AP-26113)是?种有效,选择性的,具有

?服活性的ALK抑制剂,IC50值为0.6nM。Brigatinib可?于??细胞肺癌(NSCLC)的研究[1]。

体外研究Stableheavyisotopesofhydrogen,carbon,andotherelementshavebeenincorporatedintodrugmolecules,

largelyastracersforquantitationduringthedrugdevelopmentprocess.Deuterationhasgainedattention

becauseofitspotentialtoaffectthepharmacokineticandmetabolicprofilesofdrugs.

REFERENCES

[1].RussakEM,etal.ImpactofDeuteriumSubstitutiononthePharmacokineticsofPharmaceuticals.AnnPharmacother.2019;53(2):211-

216.